1254977-71-3

Upstream product

• 1403598-30-0 4-(3-fluoro-2-methoxyphenyl)piperidine hydrochloride 
• 1403598-31-1 2-bromo-4-[4-(3-fluoro-2-methoxyphenyl)piperidin-1-yl]pyridine-3-carbonitrile 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 1403598-32-2 4-[4-(3-fluoro-2-methoxyphenyl)piperidin-1-yl]-2-hydrazinopyridine-3-carbonitrile 
• 1403598-33-3 N'-{3-cyano-4-[4-(3-fluoro-2-methoxyphenyl)piperidin-1-yl]-pyridin-2-yl}-3,3,3-trifluoropropanehydrazide 
• 1403598-29-7 tert-butyl 4-(3-fluoro-2-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 845829-94-9 1-bromo-3-fluoro-2-methoxybenzene 
• 1376335-27-1 4-(3-fluoro-2-methoxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging

The synthesis and in vitro and in vivo evaluation of a new series of 7-(phenylpiperidinyl)-1,2,4-triazolo[4,3-a]pyridines, which were conveniently radiolabeled with carbon-11, as potential positron emission tomography (PET) radiotracers for in vivo imagin

1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.